Clinical Trial

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Study acronym: ALPS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-26.
Trial Details
NCT Number NCT07448935
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions AL Amyloidosis, POEMS Syndrome, Multiple Myeloma
Enrollment 100 participants
Start Date 2025-11-28
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06